Catalent Clarifies Novo Nordisk Ownership of Former Bloomington, Indiana Site
October 14, 2025 — Catalent, a leading global contract development and manufacturing organization (CDMO), today issued a statement to address recent inaccuracies in media coverage regarding the ownership of one of its former sites located in Bloomington, Indiana.
As of December 2024, the Bloomington, Indiana site is no longer part of Catalent’s network. The site is now fully owned and operated by Novo Nordisk following the acquisition of Catalent by Novo Holdings in 2024, and the strategic divestiture of the Bloomington site and two other sterile fill-finish sites to Novo Nordisk.
Despite having announced and confirmed the ownership change, some recent reports continue to reference the Bloomington facility as part of Catalent’s network. These references are inaccurate and outdated. While legacy naming conventions such as “Catalent Indiana” or “Catalent Indiana, LLC” may still appear in certain regulatory filings, Catalent has no ownership, operational involvement, or oversight of the site.
Catalent remains a premier CDMO with over 40 facilities worldwide, delivering innovative solutions for pharma, biologics, and consumer health organizations. Catalent’s teams across the globe are committed to driving improved outcomes for customers and patients through an unwavering commitment to service excellence and a patient-first approach.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
Media Contact:
Laura Hortas
[email protected]